Whitehawk Therapeutics (WHWK) Research & Development (2016 - 2026)

Whitehawk Therapeutics (WHWK) has reported Research & Development for 11 consecutive years, with $17.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 96.09% year-over-year to $17.2 million; the TTM figure through Mar 2026 stood at $99.4 million (up 115.05% YoY), while the FY2025 annual figure was $91.0 million, up 78.25% from the prior year.
• Research & Development slipped to $17.2 million in Q1 2026 per WHWK's latest filing, from $19.0 million in the prior quarter.
• Across five years, Research & Development topped out at $48.8 million in Q2 2025 and bottomed at $6.8 million in Q1 2022.
• Historically, Research & Development has averaged $14.2 million across 5 years, with a median of $12.8 million in 2023.
• On a YoY basis, Research & Development climbed as much as 272.79% in 2025 and fell as far as 35.35% in 2025.
• Whitehawk Therapeutics' Research & Development stood at $9.4 million in 2022, then soared by 36.26% to $12.8 million in 2023, then rose by 12.37% to $14.3 million in 2024, then jumped by 32.58% to $19.0 million in 2025, then retreated by 9.41% to $17.2 million in 2026.
• Business Quant data shows WHWK's Research & Development at $17.2 million in Q1 2026, $19.0 million in Q4 2025, and $14.3 million in Q3 2025.